Mauna Kea Technologies SA (MKEAF)
- Business Wire
Mauna Kea Technologies Announces its 2022 Financial Calendar
PARIS & BOSTON, January 24, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of its 2022 Financial Calendar.
- Business Wire
Mauna Kea Technologies Reports Fourth Quarter and Full Year 2021 Sales
PARIS & BOSTON, January 20, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced fourth quarter and full year 2021 sales.
- Business Wire
Mauna Kea Technologies Provides Business Update
PARIS & BOSTON, January 13, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a board-approved plan designed to reduce operating expenses and maximize capital resources in order to support the Company's strategic focus on the use of Cellvizio as an aid for real-time characterization of lung cancer and for molecular imaging g
